The World Health Organization (WHO) is almost in fisticuffs over recent accusations that it exaggerated the H1N1 threat. “The world is going through a real pandemic,” said Dr. Fukuda, the WHO’s special adviser on pandemic influenza. “The description of it as fake is both wrong and irresponsible.”
On January 15th the US Center for Disease Control (CDC) released the latest statistics– based on two nationwide telephone surveys–about H1N1 fatalities, infection rates and inoculations covering the first eight months of the “pandemic” from April through mid-December. According to the surveys, about 55 million people contacted the infectious virus, nearly 246,000 needed hospitalization and around 11,160 died from the flu.
Do these statistics sound like a pandemic? CDC estimated that about 36,000 people died of seasonal flu-related causes each year during the 1990s in the US. So why don’t we have a pandemic alert every year? It makes you wonder: Is the CDC and WHO collaborating with big pharma companies like Glaxo Smith Kline? Surely GSK can afford to bank roll them with the profits they are making from their H1N1 vaccine.
Meanwhile, health officials and hospitals nationwide report that the outbreak has waned.
For instance, Des Moines’ main hospitals are loosening their visitor policies and Tarrant County, Texas is closing six locations that have been administering the H1N1 vaccine because their health department says the number of people wanting the vaccine had dropped off.
At the end of January, the Council of Europe will be debating “Faked Pandemics: a threat to health”, and WHO officials have been asked to testify. Dr. Fukuda has denied that the WHO was influenced by the pharma industry in declaring a pandemic.
Health officials warn that a third wave of H1N1 is coming. If it does, the WHO is off the hook. If it doesn’t hit, I guess they’ve got a lot of explaining to do.
“It’s one of the greatest medical scandals of the century” said Wolfgang Wodarg, head of health at the Council of Europe, and it’s likely the costliest. In France alone, health officials spent 1.25 billion dollars on 94 million doses of the H1N1 vaccine, but only 5 million has been used. Now, like other countries such as the UK and Germany, it is trying to sell off the supply. But the epidemic has already spiked so who wants to buy?
What I find most incredulous is how governments have been so freakin’ gullible! How could they get sucked in by big pharma companies such as Glaxo Smith Kline, Sanofi and Baxter—with their obvious financial interests at stake? Even Obama got sucked in. In October 2009, our president called H1N1 a national emergency and said there is “rapid increase in illness from H1N1…the pandemic continues to evolve and rise rapidly…” But the numbers didn’t add up—you don’t call it a pandemic without doing some research.
These drug companies told everyone initially that two vaccines were needed, but later it was discovered that one shot is enough. So they doubled their money. And just to be on the safe side, that clever Glaxo Smith Kline sold governments a “no return” policy.
Health officials were led to believe that thousands upon thousands of people would die from H1N1 and in total, $20 billion was spent on the vaccine. But so far just 13,000 worldwide have died from the virus—definitely not the killer flu predicted. Besides, 250,000 people die of seasonal flu each year and Wodarg emphasizes this fact: “It’s [H1N1] just a normal kind of flu,” he said. “It does not cause a tenth of deaths caused by the classic seasonal flu.”
Some people (and not just conspiracy theorists) believe the swine flu outbreak was a ‘false pandemic’ driven by drug companies that stood to make billions of dollars from a worldwide scam. Wodarg is one of them, and he is backed by Read the rest of this entry »
Big Pharma breathed a big sigh of relief when it realized vaccines can give a lot more bang for the buck than many “blockbuster” drugs. For pharmaceutical companies like Wyeth (now owned by Pfizer), Glaxo, Sanofi-Aventis and Novartis AG, pandemic flu threats–H1N1 in particular–couldn’t have come at a better time.
For instance, Wyeth’s pediatric pneumococcal vaccine Prevnar makes over $3 billion in annual sales–that should help cover product liability claims for its diet drug Fen-phen. (To date, the drug giant has set aside $21 billion to cover claims.)
And Merck & Co, already making shingles and cervical cancer vaccines, recently got into the US market via a deal to distribute seasonal flu vaccine made by Australia’s CSL Ltd, just in time to pay $4.85 billion in its Vioxx claims.
“Vaccines, vaccines, wonderful business,” quipped Chris Viehbacher, CEO of Sanofi-Aventis, which anticipates earnings of $6 billion in vaccine revenues this year and double its sales by 2013. In the last quarter of 2009, its H1N1 vaccines sales reached $500 million.
Novartis expected to generate $700m in fourth-quarter sales alone from its H1N1 vaccine, but GlaxoSmithKline is the main player in vaccines, holding 22 percent of the global market, and is set to cash in with Brazil, China and India as their burgeoning economies spell bigger budgets for healthcare spending. Glaxo is betting big time on the vaccine business: it just purchased a vaccine operation in Quebec for $1.4 billion, which may tighten the purse strings after paying almost $1billion to resolve lawsuits over its antidepressant Paxil.
Other big spenders are Abbott Laboratories ($6.6 billion on Belgian flu vaccine maker Solvay) and Johnson & Johnson (it just bought 18 percent of Dutch vaccine firm Crucell). “More companies are investing in vaccines as a way of diversifying away from prescription drugs,” says Michael Boyd of the International Federation of Pharmaceutical Manufacturers & Associations. “New technologies, such as cell culture, are enabling them to produce more sophisticated vaccines.”
With nearly 1 billion doses of H1N1 vaccine ordered in 2009, analysts predict the global vaccine industry will reach $40 billion by 2012: Cha ching. Perhaps this means we won’t see so many “blockbuster” new drugs entering the market in the next few years. After all, product liability litigation has been expensive.
Santa baby’s lap may just be a veritable petri dish of dancing bacteria this season—and the Santas are all too aware of it and none too pleased. In fact, AP reports that some Santas are seeking priority level status for the H1N1 flu vaccine. And can you blame them?
This weekend kicks off the official arrival of an army of Santas (“helpers” for those under the age of eight) in shopping malls nationwide—and the long lines of kids waiting to tell Santa what they want for Christmas. It’s an age old tradition and one every child looks forward to. And every parent enjoys spending the $8.99 + tax for the “framed” photo.
But this year, things are different. Now there’s alarm. Over both seasonal flu and H1N1. And who more likely to be exposed to whatever bacteria’s brewing than Santa?
Now, to be clear, the Santas who are seeking priority status for the H1N1 vaccine, AP reports, don’t want to be prioritized ahead of groups already classified as such—i.e., child care providers or those with respiratory conditions, etc. They’re also concerned about, well, those bellies like bowlfuls of jelly—yes, Santas—at least the larger bellied ones who fit the traditional character sketch for Santa—may be affected more severely should they come down with H1N1 as obesity has been linked to an increase in H1N1 complications.
I’d hate to see parents—even at the risk of shelling over that $8.99 + tax—avoid the Santa experience this year. It’s one of the few moments of true wonderment, excitement and glee a child can experience. And I’d hate to see Santa (or any of his clones) come down with H1N1.
Who knew the job of Santa could have such occupational hazards?
When you think of the H1N1 vaccine—do the terms assault and battery also come to mind? Likely not. Well, apparently there are some instances where parents who decided their children should not receive the swine flu vaccine found that their kids had been inoculated by accident. And that constitutes battery, at least according to a New York medical malpractice lawyer. He has issued a press release on the subject, so I would assume this is not an uncommon problem.
The incident of a Brooklyn school girl is cited in the press release. Apparently, her parents didn’t sign her up for the vaccine, but she wound getting it anyways and ended up in a hospital. She has epilepsy and one assumes the vaccine somehow caused a serious adverse reaction.
“Any unlawful touching or unauthorized administration of medical care not in an emergency situation is a battery, a legal term for an assault. A school district cannot unilaterally administer vaccinations without parental consent, in writing,” the lawyer explained. “If there is a battery,†he is quoted as saying, (medicine given to a child without an emergency situation, or parental consent), “by law the child is entitled to compensatory damages.”
Now I would emphasize that the lawyer is only commenting on situations in New York City elementary schools, to the best of my knowledge. And, as always, there are exceptions to the rules, in that in the event of an emergency—schools would be able to provide medical care to the student since they are acting “in loco parentis”—which means instead of the parent—while a child is in their care.
The lawyer also warns that school districts and their municipalities are heavily protected against lawsuits…no surprise there…so filing a lawsuit should be a carefully considered decision, as it should be in any event.
And, there is a statute of limitations for filing a lawsuit:
“Vaccinating a child without parental consent is a tort that has a one-year statute of limitations. But because the school is part of the City, a parent only has 90 days from the time of the battery to file a Notice of Claim.” And, 90 days means 90 days, not three months.